Search results for "NOMA"

showing 10 items of 6328 documents

Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin.

2021

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing challenge in terms of prevention and treatment. A minority of affected patients develops inflammation, subsequently fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCC is a leading cause of cancer-related death. An increased number of senescent cells correlate with age-related tissue degeneration during NAFLD-induced HCC. Senolytics are promising agents that target selectively senescent cells. Previous studies showed that whereas a combination of the senolytic drugs dasatinib and quercetin (D + Q) reduced NAFLD in mice, D + Q lacked efficacy in removing doxorubicin-induced…

0301 basic medicineMaleAgingCirrhosisDasatiniblcsh:MedicineBiochemistrySenolytics.Liver disease0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseSenotherapeuticsNonalcoholic fatty liver diseaseDiethylnitrosamineCancerlcsh:CytologyLiver Diseases3. Good healthDasatinib030220 oncology & carcinogenesisHepatocellular carcinomaDisease ProgressionQuercetinmedicine.symptomLiver diseasemedicine.drugShort ReportInflammationDiet High-Fat03 medical and health sciencesmedicineAnimalsObesitylcsh:QH573-671SenolyticMolecular BiologyInflammationbusiness.industrySenolyticslcsh:RCell Biologymedicine.diseasedigestive system diseasesMice Inbred C57BLDisease Models Animal030104 developmental biologyGene Expression RegulationCancer researchbusinessCell communication and signaling : CCS
researchProduct

Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.

2019

The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. ispartof: EUROPEAN JOURNAL OF CANCER vol:124 pages:67-…

0301 basic medicineMaleCancer ResearchEsophageal NeoplasmsADJUVANT CHEMOTHERAPY0302 clinical medicineEUROPEAN ORGANIZATIONMultidisciplinary approachGastricPerioperativeStage (cooking)AdjuvantClinical OncologyMISMATCH REPAIR DEFICIENCYdigestive oral and skin physiologyGastro oesophageal junctionOPEN-LABELPrognosisJCOGhumanitiesEORTCOncology030220 oncology & carcinogenesisCLINICAL-RESEARCHFemaleImmunotherapyEsophagogastric JunctionRANDOMIZED PHASE-IILife Sciences & Biomedicinemedicine.medical_specialtyStage ii03 medical and health sciencesStomach NeoplasmsmedicineChemotherapyHumansNeoplasm StagingScience & Technologybusiness.industryPERIOPERATIVE CHEMOTHERAPYGeneral surgeryCancerADENOCARCINOMAPLUS OXALIPLATINmedicine.diseaseSurvival Analysisdigestive system diseases030104 developmental biologyNeoplasm stagingbusinessTRIAL DESIGNEuropean journal of cancer (Oxford, England : 1990)
researchProduct

NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance

2016

AbstractSorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). However, its benefits are modest, and as its mechanisms of action remain elusive, a better understanding of its anticancer effects is needed. Based on our previous study results, we investigated here the implication of the nuclear protein 1 (NUPR1) in HCC and its role in sorafenib treatment. NUPR1 is a stress-inducible protein that is overexpressed in various malignancies, but its role in HCC is not yet fully understood. We found that NUPR1 expression was significantly higher in primary human HCC samples than in the normal liver. Knockdown of NUPR1 signi…

0301 basic medicineMaleCancer ResearchHepatocellular carcinomaCore Binding Factor Alpha 1 Subunit0302 clinical medicineCell MovementBasic Helix-Loop-Helix Transcription FactorsMolecular Targeted TherapyRNA Small InterferingRegulation of gene expressionAged 80 and overGene knockdownRELBLiver NeoplasmsMiddle AgedSorafenib3. Good healthNeoplasm ProteinsSorafenib.Gene Expression Regulation Neoplastic030220 oncology & carcinogenesisGene Knockdown TechniquesOriginal ArticleFemalemedicine.drugSorafenibNiacinamideCarcinoma HepatocellularRUNX2 GeneCell SurvivalIER3ImmunologyDown-RegulationBiology03 medical and health sciencesCellular and Molecular NeuroscienceYoung AdultmedicineGene silencingHumansNeoplasm InvasivenessGene SilencingneoplasmsAgedCell ProliferationCell growthGene Expression ProfilingPhenylurea CompoundsTranscription Factor RelBComputational BiologyMembrane ProteinsCell BiologyNuclear protein-1digestive system diseases030104 developmental biologyDrug Resistance NeoplasmCancer researchApoptosis Regulatory ProteinsTranscriptomeCell Death & Disease
researchProduct

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational …

2019

Abstract Background Regorafenib prolonged overall survival (OS) versus placebo in patients with treatment-refractory metastatic colorectal cancer (mCRC) in phase III trials. We conducted an observational study of regorafenib for patients with mCRC in real-world clinical practice. Methods The international, prospective, CORRELATE study recruited patients with mCRC previously treated with approved therapies, for whom the decision to treat with regorafenib was made by the treating physician according to the local health authority approved label. The primary objective was safety, assessed by treatment-emergent adverse events (TEAEs; National Cancer Institute Common Terminology Criteria for Adve…

0301 basic medicineMaleCancer ResearchLung NeoplasmsColorectal cancerPyridinesGTP Phosphohydrolaseschemistry.chemical_compound0302 clinical medicineObservational studyProspective StudiesNeoplasm MetastasisFatiguePeritoneal NeoplasmsRegorafenibAged 80 and overLiver NeoplasmsCommon Terminology Criteria for Adverse EventsMiddle AgedProgression-Free SurvivalOncology030220 oncology & carcinogenesisHypertensionFemaleHand-Foot SyndromeColorectal NeoplasmsAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyBone NeoplasmsPlaceboProto-Oncogene Proteins p21(ras)03 medical and health sciencesYoung AdultRegorafenibInternal medicinemedicineHumansAdverse effectSurvival analysisAgedAdverse effectsbusiness.industryPhenylurea CompoundsCarcinomaCancerMembrane ProteinsSurvival analysismedicine.disease030104 developmental biologychemistryObservational studyLymph NodesbusinessAdverse effects; Observational study; Regorafenib; Survival analysisEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcino…

2018

Abstract In solid tumors, the presence of lymph node–like structures called tertiary lymphoid structures (TLS) is associated with improved patient survival. However, little is known about how TLS develop in cancer, how their function affects survival, and whether they are affected by cancer therapy. In this study, we used multispectral microscopy, quantitative pathology, and gene expression profiling to analyze TLS formation in human lung squamous cell carcinoma (LSCC) and in an experimental model of lung TLS induction. We identified a niche of CXCL13+ perivascular and CXCL12+LTB+ and PD-L1+ epithelial cells supporting TLS formation. We also characterized sequential stages of TLS maturation…

0301 basic medicineMaleCancer ResearchLung Neoplasmsmedicine.medical_treatmentApoptosis03 medical and health sciencesMiceLymphocytes Tumor-InfiltratingAdrenal Cortex HormonesCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsCarcinomaTumor Cells CulturedTumor MicroenvironmentMedicineAnimalsHumansCXCL13Lung cancerSurvival rateAgedCell ProliferationChemotherapyTumor microenvironmentbusiness.industryGene Expression ProfilingCancerGerminal centerMiddle Agedmedicine.diseaseGerminal CenterPrognosisXenograft Model Antitumor Assays3. Good healthMice Inbred C57BLSurvival Rate030104 developmental biologyTertiary Lymphoid StructuresOncologyCancer researchCarcinoma Squamous CellFemalebusinessFollow-Up StudiesCancer research
researchProduct

Exome-wide somatic mutation characterization of small bowel adenocarcinoma

2018

Small bowel adenocarcinoma (SBA) is an aggressive disease with limited treatment options. Despite previous studies, its molecular genetic background has remained somewhat elusive. To comprehensively characterize the mutational landscape of this tumor type, and to identify possible targets of treatment, we conducted the first large exome sequencing study on a population-based set of SBA samples from all three small bowel segments. Archival tissue from 106 primary tumors with appropriate clinical information were available for exome sequencing from a patient series consisting of a majority of confirmed SBA cases diagnosed in Finland between the years 2003–2011. Paired-end exome sequencing was…

0301 basic medicineMaleCancer ResearchMICROSATELLITE INSTABILITYColorectal canceroncogenesReceptor ErbB-2medicine.disease_causeCOLORECTAL-CANCERACTIVATIONCohort Studies0302 clinical medicineAnimal CellsAdenocarcinomasMedicine and Health SciencesExomeFrameshift MutationExomeGenetics (clinical)Exome sequencingAged 80 and overSMALL-INTESTINEeducation.field_of_study1184 Genetics developmental biology physiologyCELIAC-DISEASENonsense MutationMiddle Aged3. Good healthsyöpägeenitOncology030220 oncology & carcinogenesissyöpätauditFemaleSIGNALING PATHWAYKRASCellular TypesResearch ArticleAdultProto-Oncogene Proteins B-raflcsh:QH426-470SEQUENCING DATAImmune CellsNonsense mutationPopulationImmunologyAntigen-Presenting CellsComputational biologysuolistosyövätBiologyAdenocarcinomata3111CarcinomasFrameshift mutation03 medical and health sciencesGermline mutationQUALITY-CONTROLGenetiikka kehitysbiologia fysiologia - Genetics developmental biology physiologySyöpätaudit - CancersIntestinal NeoplasmsmedicineGeneticsPoint MutationHumanseducationMolecular BiologyEcology Evolution Behavior and SystematicsAgedColorectal CancerBiology and Life SciencesCancers and Neoplasmscancerous diseasesCell Biologymedicine.diseaseta3122mutationsCOMPREHENSIVE MOLECULAR CHARACTERIZATIONlcsh:Genetics030104 developmental biologyMutationSomatic Mutationbowel cancer3111 BiomedicinemutaatiotHIGH-RESOLUTIONPLoS Genetics
researchProduct

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

2019

Abstract Purpose: Hyperprogression (HP), a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors (ICI). Neither clinicopathologic features nor biological mechanisms associated with HP have been identified. Experimental Design: Among 187 patients with non–small cell lung cancer (NSCLC) treated with ICI at our institute, cases with HP were identified according to clinical and radiologic criteria. Baseline histologic samples from patients treated with ICI were evaluated by IHC for myeloid and lymphoid markers. T-cell–deficient mice, injected with human lung cancer cells and patient-derived xenografts (PDX) belonging to specific mutat…

0301 basic medicineMaleCancer ResearchMyeloidLung NeoplasmsCD33Programmed Cell Death 1 ReceptorFc receptorMice NudeMice SCIDReceptors Fcnon-small cell lung cancer Hyperprogression immune checkpoint inhibitors.B7-H1 AntigenArticle03 medical and health sciences0302 clinical medicineImmunophenotypingAntineoplastic Agents ImmunologicalPD-L1Carcinoma Non-Small-Cell LungCell Line TumormedicineAnimalsHumansLung cancerAntibodies Blockingbiologybusiness.industryMacrophagesmedicine.diseaseXenograft Model Antitumor Assays3. Good healthImmunoglobulin Fc FragmentsTumor Burden030104 developmental biologymedicine.anatomical_structureNivolumabOncology030220 oncology & carcinogenesisbiology.proteinCancer researchImmunohistochemistryFemaleAntibodybusinessClinical Cancer Research
researchProduct

Thyroid Cancer in the Pediatric Age in Sicily: Influence of the Volcanic Environment.

2017

Background/Aim: Pediatric thyroid cancer (TC) is rare but its incidence is increasing. We analyzed incidence and characteristics of pediatric TC in Sicily and comparatively evaluated data from the volcanic and non-volcanic areas. Materials and Methods: All incident pediatric (0-19 years) TCs in Sicily between 2002-2009 were analyzed for the area of residence and compared to data for adults. Results: A total of 54 differentiated TCs (DTC) and nine medullary TCs were diagnosed in Sicily in children between 2002-2009. DTC age standardized rate for the world population (ASRw) was 0.8/105 in females and 0.2/105 in males, with a higher incidence in the volcanic area (ASRw=1.4/105 in females, 0.5/…

0301 basic medicineMaleCancer ResearchPapillaryPediatricsCohort Studies0302 clinical medicineRisk FactorsMedicineRegistriesChildThyroid cancerSicilygeography.geographical_feature_categoryThyroid cancer epidemiologyGeographyIncidence (epidemiology)IncidencePediatric ageGeneral MedicineOncology030220 oncology & carcinogenesisChild PreschoolEvaluated dataFemaleStandardized ratePediatric thyroid cancer; Thyroid cancer and volcanic environment; Thyroid cancer epidemiologyThyroid cancer and volcanic environmentAdolescentPediatric thyroid cancer; Thyroid cancer and volcanic environment; Thyroid cancer epidemiology; Adolescent; Carcinoma Papillary; Child; Child Preschool; Cohort Studies; Female; Geography; Humans; Incidence; Infant; Infant Newborn; Male; Pediatrics; Registries; Risk Factors; Sicily; Thyroid Neoplasms; Volcanic Eruptions; Young Adult; Oncology; Cancer ResearchVolcanic Eruptions03 medical and health sciencesYoung AdultArea of residenceHumansThyroid NeoplasmsPreschoolgeographybusiness.industryfungiCarcinomaInfant NewbornInfantmedicine.diseaseNewbornCarcinoma Papillary030104 developmental biologyVolcanoPediatric thyroid cancerbusinessDemographyAnticancer research
researchProduct

JC Virus and Lung Adenocarcinoma: Fact or Myth?

2017

Background/aim An association has been reported between lung cancer and John Cunningham (JC) virus infection. The aim of this study was to evaluate the prevalence of JC virus in a small cohort of patients with lung adenocarcinoma and assess its presence in nodal metastasis. Materials and methods Consecutive samples of 13 surgically-removed lung tumors and 13 surrounding normal cancer-free tissues were selected. Five cases included metastatic lymph nodes. JC virus infection was assessed through nested PCR. Results Seven out of thirteen patients with lung adenocarcinoma had a positive PCR test for JC virus. One of the five patients with nodal metastasis had a positive PCR test for JC virus. N…

0301 basic medicineMaleCancer ResearchPathologymedicine.medical_specialtyTumor Virus InfectionsLung NeoplasmsvirusesJC virusAdenocarcinoma of Lung030230 surgeryAdenocarcinomamedicine.disease_causePolymerase Chain ReactionVirus03 medical and health sciences0302 clinical medicinemedicineHumansLung cancerAgedPolyomavirus InfectionsLungbusiness.industryJC Virus InfectionGeneral Medicinemedicine.diseaseJC VirusTumor Virus Infections030104 developmental biologymedicine.anatomical_structureOncologyCase-Control StudiesLymphatic MetastasisDNA ViralAdenocarcinomaFemalebusinessPolyomavirus InfectionsAnticancer research
researchProduct

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.

2020

Abstract Background Elevated lactate dehydrogenase (LDH) is a known predictive and prognostic factor for a poor outcome in patients with metastatic melanoma. It is unclear whether first-line targeted therapy (TT) or immune checkpoint inhibition (ICI) is more beneficial in melanoma patients with elevated LDH because prospective studies in this area are lacking. Methods This multicentre retrospective cohort study was conducted at 25 melanoma centres worldwide to analyse progression-free survival (PFS) and overall survival (OS) among melanoma patients with elevated LDH. The role of confounders was addressed by using inverse probability of treatment weighting. Results Among 173 BRAFV600-mutant …

0301 basic medicineMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentProgrammed Cell Death 1 ReceptorMedizinGastroenterologyTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective cohort studyImmune Checkpoint InhibitorsMelanomaAgedRetrospective Studiesbusiness.industryMelanomaConfoundingRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisImmune checkpoint3. Good healthBlockadeSurvival Rate030104 developmental biologyOncologyCTLA-4030220 oncology & carcinogenesisDrug Therapy CombinationFemaleImmunotherapybusinessFollow-Up StudiesEuropean journal of cancer (Oxford, England : 1990)
researchProduct